Akorn has forecast earnings improving further in 2019 after reporting better-than-expected first-quarter results, at the same time as it is making “sustained” progress in fixing quality-control problems that have landed the firm in trouble with the US Food and Drug Administration.
The Lake Forest, Illinois-based company posted a net loss of $82m in the three months to 31 March, much higher...







